Published in final edited form as:

Am J Obstet Gynecol. 2013 July ; 209(1): 51.e1–51.e6. doi:10.1016/j.ajog.2013.03.011.

Risk Factors for Uterine Atony/Postpartum Hemorrhage Requiring Treatment after Vaginal Delivery

Luisa A Wetta, MD¹, Jeff M Szychowski, PhD², Ms. Samantha Seals, MS², Melissa S Mancuso, MD¹, Joseph R Biggio, MD¹, and Alan TN Tita, MD, PhD¹

¹Center for Women's Reproductive Health and Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham

²Department of Biostatistics, University of Alabama at Birmingham Birmingham, Alabama

Abstract

Objective—To identify risk factors for uterine atony or hemorrhage.

Study Design—Secondary analysis of a 3-arm double-blind randomized trial of different dose-regimens of oxytocin to prevent uterine atony after vaginal delivery. The primary outcome was uterine atony or hemorrhage requiring treatment. Twenty-one potential risk factors were evaluated. Logistic regression was used to identify independent risk factors using 2 complementary pre-defined model selection strategies.

Results—Among 1798 women randomized to 10, 40 or 80U prophylactic oxytocin after vaginal delivery, treated uterine atony occurred in 7%. Hispanic (OR 2.1; 95% CI 1.3–3.4) and non-Hispanic whites (OR 1.6; 95% CI 1.0–2.5), preeclampsia (OR 3.2; 95% CI 2.0–4.9) and chorioamnionitis (OR 2.8; 95% CI 1.6–5.0) were consistent independent risk factors. Other risk factors based on the specified selection strategies were obesity, induction/augmentation of labor, twins, hydramnios, anemia, and arrest of descent. Amnioinfusion appeared to be protective against uterine atony (OR 0.53; 95% CI 0.29–0.98).

Conclusion—Independent risk factors for uterine atony requiring treatment include Hispanic and non-Hispanic white ethnicity, preeclampsia and chorioamnionitis.

Keywords

Postpartum hemorrhage; Risk factors; Uterine Atony

Introduction

The incidence of postpartum hemorrhage in developed countries is increasing.^{1,2,3,4} In the United States, one estimate of the overall rate of postpartum hemorrhage increased

© 2013 Mosby, Inc. All rights reserved.

Corresponding author/Request for reprints: Luisa Wetta, MD, 176 F 10270T, 619 19th Street South, Birmingham, AL 35249-7333, Phone: 205-934-9482, Fax: 205-975-4375, lwetta@uabmc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosure: The authors report no conflict of interest

Presented in part as a poster at the Society for Maternal-Fetal Medicine 31st Annual Meeting, February 7–12, San Francisco, CA 2011.

approximately 26%, from 2.3% in 1994 to 2.9% in 2006.¹ Uterine atony may specifically account for up to 80% of the cases of postpartum hemorrhage.^{5,6} Unlike other causes of obstetric hemorrhage such as placental abnormalities which may be detected prenatally, uterine atony is difficult to predict.⁷ Many risk factors for uterine atony and postpartum hemorrhage have been reported.^{8,9,10,11,12,13,14,15} The specific risk factors examined and the magnitude of risk attributable to each of them vary across reports. Therefore confounding may be a major reason for the discrepancies. Furthermore, reports of true risk factors may be missed in some studies because of limited power to demonstrate statistical significance.

A greater understanding of well-defined independent risk factors may improve our ability to determine which women may be at risk for postpartum hemorrhage. This is important since obstetrical hemorrhage, primarily postpartum, is a significant cause of maternal morbidity and mortality worldwide.^{8,16,17,18,19} Therefore the purpose of this study was to conduct a more comprehensive multivariable analysis to identify independent risk factors for uterine atony or postpartum hemorrhage. We applied multivariable statistical models that allowed us to identify probable independent risk factors that may be confirmed in larger studies.

Material and Methods

We conducted a secondary analysis of a three-arm double blind randomized clinical trial of different doses of oxytocin at University Hospital, Birmingham, AL.²⁰ The primary aim of the trial was to evaluate higher doses of oxytocin compared to a standard low dose oxytocin regimen used for prophylaxis among women undergoing vaginal delivery. Women were randomized to a 10 unit (standard), 40 unit, or 80 unit dose regimen of oxytocin at vaginal delivery. Women were excluded if they were less than 24 weeks gestation, underwent a cesarean delivery, had a fetal demise, had pulmonary edema, or a coagulopathy or cardiomyopathy. Each regimen comprised the specified dose in 500mL of a crystalloid solution administered rapidly over 1 hour after delivery of the placenta (i.e. at a rate of 500cc per hour). The protocol was approved by the Institutional Review Board at the University of Alabama at Birmingham (UAB). All participating women granted informed consent. Information concerning patient demographic and clinical characteristics as well as outcomes of interest, including postpartum hemorrhage or atony requiring therapy, were abstracted by trained research nurses. For this secondary analysis, we retained the same primary outcome: uterine atony or hemorrhage requiring treatment. Treatment included the use any use of uterotonics, or the need for transfusion, tamponade (Bakri balloon), surgery, or interventional radiology procedure for uterine or arterial embolization. Transfusion was based on the need for whole or packed red cells prior to discharge home from the hospital. The diagnosis of uterine atony was made based on the discretion of the treating obstetrical team.

The study variables or exposures of interest consisted of a large set of 21 potential risk factors (including demographic characteristics) for uterine atony/hemorrhage (listed in Table 1) identified from the published literature. The risk factors were defined accordingly: Overweight was defined as a BMI of 25–29.9 kg/m² and obesity was defined as a BMI of 30 kg/m². Ethnicity was self-reported as Hispanic, Black, White, or Other. Chorioamnionitis was defined as the presence of clinical signs (primarily intrapartum fever) leading to a clinical diagnosis and antibiotic treatment of chorioamnionitis. Anemia was determined by a Hemoglobin of <9. Hydramnios was defined as an amniotic fluid volume of >25cm or a greatest vertical pocket of > 8cm. Protracted second stage of labor was greater than 1 hour from complete cervical dilation to delivery if multiparous and greater than 2 hours between complete cervical dilation and delivery if nulliparous. A protracted third stage was defined as being greater than 30 minutes from the times of delivery of the infant to delivery of the placenta.

Logistic regression analyses were conducted to individually evaluate each of the risk factors as predictors of the primary study composite. Risk factors identified as significant, either by statistical significance at a 0.05 level or by large effect ($OR > 1.5$ or $OR < 0.7$) at the univariate level, were considered in multivariable logistic regression models. A parsimonious regression model of independent risk factors was derived using traditional backward model selection strategy whereby only factors significant at the 0.05 level at each stage were retained for further consideration.²¹ Risk factors were progressively eliminated from the model until a parsimonious model comprising only factors statistically satisfying the specific selection criteria was obtained.

To identify additional risk factors that may not be statistically significant within the limitations of our sample size, we utilized a previously-described modified backward selection strategy that gave premium to the magnitude of risk as well as to statistical significance.²² *A priori*, factors associated with a minimally important change in the outcome (defined as $OR = 1.5$ or 0.67) or a p -value < 0.05 were retained in the model. The minimally important difference was selected as we judged this level to be of public health significance. Variables with adjusted odds ratios (aORs) < 1.5 and > 0.67 were then progressively removed, starting with the variable with the highest P value until the final parsimonious models were obtained. SAS software (version 9.2; SAS Institute Inc, Cary, NC) was used for all statistical analyses.

Results

Our study sample included all 1798 women randomized and analyzed in the primary trial. Six hundred fifty-eight women were randomized to 80 units of oxytocin, 481 women to 40 units (this arm was terminated at interim review), and 659 to 10 units of oxytocin. The distribution of the population according to characteristics under study is presented in Table 1. Of note, the dose of prophylactic oxytocin did not influence the outcome in the primary trial. The study population consisted of women who were predominantly obese, African American, underwent labor induction and received an epidural.

The frequency of the primary outcome, treated uterine atony or hemorrhage, was 7% overall (118 women) and did not differ by study group.²⁰ The prevalence of this outcome by categories of each of the 21 potential risk factors for uterine atony/hemorrhage and the corresponding unadjusted OR (95% CI) are presented in Table 2. BMI, race/ethnicity, labor induction, twins, preeclampsia, breastfeeding, anemia, protracted 2nd stage, and chorioamnionitis were significantly associated with postpartum atony or hemorrhage in univariate analyses.

Using traditional backward selection (strategy A), Hispanic (aOR 2.10, 95% CI 1.30–3.37) and Non-Hispanic white ethnicity (aOR 1.59, 95% CI 1.00–2.53), preeclampsia (aOR 3.15; 95% CI: 2.00, 4.95) and chorioamnionitis (aOR 2.83, 95% CI 1.61–4.97) were the only independent risk factors for treated uterine atony or obstetric hemorrhage in the final parsimonious model (Table 3).

Applying the modified backward selection (strategy B) to identify additional risk factors, obesity, labor induction, twins, hydramnios, anemia and protracted 2^d stage of labor were identified as risk factors for uterine atony or obstetric hemorrhage (in addition to race/ethnicity, preeclampsia and chorioamnionitis); amnioinfusion appeared protective based on the pre-defined criteria for selecting risk factors (Table 3).

Magnesium sulfate was used in 10% of the deliveries; however, preeclampsia is highly correlated with use of magnesium sulfate in our study sample (Spearman correlation 0.84, $p < 0.0001$). To avoid multicollinearity in the statistical models, these two factors were

considered separately. When magnesium sulfate replaced preeclampsia in the final models it was also associated with atony/postpartum hemorrhage with both strategy A (aOR 3.0; 95% CI: 1.9–4.8) and strategy B (aOR 2.4; 95% CI: 1.4–4.0). Results for the other covariates identified in prior models were similar.

In additional analyses not shown, we evaluated women with a history of a prior postpartum hemorrhage. There were only a small number of women, 7, who reported this history. When a history of postpartum hemorrhage was assessed using traditional backward selection (strategy A), it was not identified as a risk factor. However, using strategy B, the adjusted OR was 2.0, 95% CI 0.2–19.1. Overall the associations of other risk factors did not change materially, but the model became less stable because of the small number of women.

Comment

Out of 21 demographic and clinical factors examined, maternal race/ethnicity, preeclampsia and chorioamnionitis were consistent risk factors for uterine atony or postpartum hemorrhage requiring treatment in our cohort of women who underwent vaginal delivery. When we applied a modified model selection strategy that emphasized strength of association over statistical significance, we identified additional risk factors. Prophylactic oxytocin doses did not influence the results as reported in the primary paper.²⁰

Uterine atony as the cause of primary postpartum hemorrhage is increasing in the United States and other countries such as Canada and Australia.^{1,2,23} Interventions such as induction of labor, cesarean delivery, and operative vaginal delivery have been implicated, but the cause of this increase remains unclear.^{24,25} Additionally, advanced maternal age, multiple gestation, prior hemorrhage and prolonged labor have also been cited as risk factors.^{25,26,27} Our current findings among women with vaginal delivery support labor induction and multiple pregnancy but not operative vaginal deliveries or advanced maternal age as likely independent risk factors. Furthermore, our findings are supportive of prior studies that identified obesity, White or Hispanic race/ethnicity, polyhydramnios, preeclampsia, anemia and infection (chorioamnionitis) as potential independent risk factors but not those that identified African American ethnicity or breastfeeding.^{6,8,11,13,14,15} Because of its tocolytic effect, one would expect magnesium sulfate to be associated with an increase in the risk of atony or postpartum hemorrhage. Although our results also support studies suggesting such an association¹³, we are unable to delineate whether this is entirely or partially attributable to confounding with preeclampsia. The exact mechanism by which preeclampsia leads to atony or hemorrhage is open to speculation. Furthermore, because breastfeeding may have a uterotonic effect due to endogenous oxytocin surge, it would be expected to be associated with a reduction in the study outcome. We do not observe such an association after multivariable adjustments (breastfeeding is eliminated from the multivariable regression models), perhaps suggesting that at the doses of exogenous prophylactic oxytocin administered, there is no additional uterotonic benefit from breast feeding. Our finding suggesting amnioinfusion as a protective factor for uterine atony is surprising and does not appear to have been previously reported. If confirmed, it is plausible that amnioinfusion may “wash” away bacteria and inflammatory mediators that may predispose to infection and subsequent uterine atony. We are unable to postulate a unifying biological explanation for uterine atony. Our findings would suggest that there are likely several pathways at play. For example, both chorioamnionitis and magnesium sulfate in the setting of preeclampsia may impair uterine contractility, resulting in uterine atony and hemorrhage.

Our report suffers from a number of limitations. First, we studied only women who delivered vaginally. Therefore our results are not directly applicable to women who

underwent cesarean delivery. Although some of our findings are consistent with observations in women who delivered by cesarean, it is also possible that some of the discrepancies may be due to differences in mode of delivery. Second, our sample size may not be sufficient to evaluate potential risk factors that are less frequent. Our modified regression strategy (B) addressed this potential limitation; we were able to identify probable risk factors that did not meet traditional criteria for statistical significance but which were important contributors to the model and might attain statistical significance given a larger study population. Finally, as an exploratory secondary analysis, levels of significance for each statistical test were not adjusted for multiple comparisons. Because of the large number of statistical tests performed, it is possible that some of the observed associations occurred purely by chance. It is, however, reassuring that most of our findings are supported by the published literature.

In this study, we have simultaneously evaluated multiple potential risk factors using a well characterized contemporary sample of women enrolled in a single-center trial. We identified a short list of consistent risk factors for uterine atony or postpartum hemorrhage after eliminating factors which may have been previously associated because of uncontrolled confounding. For example, studies that did not consider preeclampsia may find African American ethnicity as a risk factor. Also, given ongoing temporal changes in obstetric demographics and practices including labor induction, epidural use and cesarean delivery, it is plausible that contemporary risk factors may vary. The identification of independent risk factors for atony and postpartum hemorrhage will allow clinicians to better anticipate who may truly be at risk for postpartum hemorrhage and more efficiently plan preventive and therapeutic measures against adverse outcomes. Our findings suggest that among vaginal deliveries, women of Hispanic or Non-Hispanic white backgrounds or whose deliveries are complicated by chorioamnionitis or preeclampsia are most at risk. Subsequent studies with relevant power are needed to confirm maternal obesity, labor induction, twins, hydramnios, anemia and protracted 2^d stage of labor as additional independent risk factors and amnioinfusion as a protective factor. The role of magnesium sulfate use independently of preeclampsia also warrants further clarification.

References

1. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994–2006. *Am J Obstet Gynecol.* 2010; 202:353.e1–353.e6. [PubMed: 20350642]
2. Joseph KS, Rouleau J, Kramer MS, Young DC, Liston RM, Baskett TF. Maternal Health Study Group of the Canadian Perinatal Surveillance System. Investigation of an increase in postpartum haemorrhage in Canada. *BJOG.* 2007; 114:751–759. [PubMed: 17516968]
3. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. *BMC Pregnancy Childbirth.* 2009; 9:55. [PubMed: 19943928]
4. Roberts CL, Ford JB, Algert CS, Bell JC, Simpson JM, Morris JM. Trends in adverse maternal outcomes during childbirth: a population-based study of severe maternal morbidity. *BMC Pregnancy Childbirth.* 2009; 9:7. [PubMed: 19243578]
5. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. *Obstet Gynecol.* 2006; 108:1039–1047. [PubMed: 17012482]
6. Bateman BT, Berman MF, Riley LE, Leffert LR. The Epidemiology of Postpartum Hemorrhage in A Large, Nationwide Sample of Deliveries. *Anesth Analg.* 2010; 110:1368–1373. [PubMed: 20237047]
7. Warshak CR, Eskander R, Hull AD, et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. *Obstet Gynecol.* 2006; 108:573–581. [PubMed: 16946217]

8. Zwart JJ, Richters LM, Ory F, de Vries JI, Bloemenkamp KW, van Roosmalen J. Severe maternal morbidity during pregnancy, delivery and puerperium in the Netherlands: A nationwide population based study of 371,000 pregnancies. *BJOG*. 2008; 115:842. [PubMed: 18485162]
9. Combs CA, Laros RK Jr. Prolonged third stage of labor: morbidity and risk factors. *Obstet Gynecol*. 1991; 77:863–867. [PubMed: 2030858]
10. Combs CA, Murphy EL, Laros RK Jr. Factors associated with postpartum hemorrhage with vaginal birth. *Obstet Gynecol*. 1991; 77:69–76. [PubMed: 1984230]
11. Stones RW, Paterson CM, Saunders NJ. Risk factors for major obstetric hemorrhage. *Eur J Obstet Gynecol Reprod Biol*. 1993; 48:15–18.
12. Combs CA, Murphy EL, Laros RK. Factors associated with hemorrhage in cesarean deliveries. *Obstet Gynecol*. 1991; 77:77–82. [PubMed: 1984231]
13. Rouse DJ, Leindecker S, Landon M, et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The MFMU Cesarean Registry: uterine atony after primary cesarean delivery. *Am J Obstet Gynecol*. 2005; 193:1056–1060. [PubMed: 16157111]
14. Al-Zirqi I, Vangen S, Forsen L, et al. Prevalence and risk factors of severe obstetric haemorrhage. *BJOG*. 2008; 115:1265. [PubMed: 18715412]
15. Chichakli LO, Atrash HK, Mackay AP, Musane AS, Berg CJ. Pregnancy-related mortality in the United States due to hemorrhage: 1979–1992. *Obstet Gynecol*. 1999; 94:721. [PubMed: 10546717]
16. Ronsmans C, Graham WJ. Lancet Maternal Survival Series steering group. Maternal mortality: who, when, where, and why. *Lancet*. 2006; 368:1189–1200. [PubMed: 17011946]
17. Brace V, Penney G, Hall M. Quantifying severe maternal morbidity: a Scottish population study. *BJOG*. 2004; 111:481–484. [PubMed: 15104614]
18. Callaghan WM, Mackay AP, Berg CJ. Identification of severe maternal morbidity during delivery hospitalizations, United states, 1991–2003. *Am J Obstet Gynecol*. 2008; 199:133.e1–133.e8. [PubMed: 18279820]
19. Zhang WH, Alexander S, Bouvier-Cole MH, Mascfarlane A. Incidence of severe pre-eclampsia, postpartum haemorrhage and sepsis as a surrogate marker for severe maternal morbidity in a European population-based study: the MOMS-B survey. *BJOG*. 2005; 112:89–96. [PubMed: 15663404]
20. Tita AT, Szychowski J, Rouse DJ, et al. Higher-Dose Oxytocin and Hemorrhage After Vaginal Delivery: A Randomized Controlled Trial. *Obstet Gynecol*. 2012; 119:293–300. [PubMed: 22227638]
21. Neter, J.; Kutner, MH.; Nachtsheim, CJ.; Wasserman, W. *Applied Linear Regression Models*. 3rd Ed. Chicago (IL): Richard D Irwin, Inc; 1996. Building the Regression Model I: Selection of Predictor Variables; p. 327-354.
22. Tita AT, Selwyn BJ, Waller DK, Kapadia AS, Dongmo S. Factors associated with the awareness and practice of evidence-based obstetric care in an African setting. *BJOG*. 2006; 113:1060–1066. [PubMed: 16956337]
23. Ford JB, Roberts CL, Simpson JM, Vaughan J, Cameron CA. Increased postpartum hemorrhage rates in Australia. *Int J Gynaecol Obstet*. 2007; 98:237–243. [PubMed: 17482190]
24. Malabarey O, Almog B, Brown R, Abenheim HA, Shrim A. Postpartum hemorrhage in low risk population. *J Perinat Med*. 2011; 39:495–498. [PubMed: 21714767]
25. Driessen M, Bouvier-Cole MH, Dupont C, Khoshnood B, Rudigoz RC, Deneux-Tharaux C. Pithagore6 Group. Postpartum hemorrhage resulting from uterine atony after vaginal delivery: factors associated with severity. *Obstet Gynecol*. 2011; 117:21–31. [PubMed: 21173641]
26. Smulian JC, Ananth CV, Kinzler WL, Kontopoulos E, Vintzileos AM. Twin deliveries in the United States over three decades: an age-period-cohort analysis. *Obstet Gynecol*. 2004; 104:278–285. [PubMed: 15292000]
27. Ventura SJ, Abma JC, Mosher WD, Henshaw SK. Estimated pregnancy rates for the United States, 1990–2005: an update. *Natl Vital Stat Rep*. 2009; 58:1–14.

Clinical Implications

- Identifying independent risk factors for uterine atony/postpartum hemorrhage allows clinicians to be better prepared to avoid adverse outcomes.
- Our modified selection strategy takes into account the limitations seen in many other studies.
- Women with chorioamnionitis, preeclampsia, or of Hispanic or Non-Hispanic white background may be most at risk for uterine atony/postpartum hemorrhage.
- Future research is needed to confirm other independent risk factors for uterine atony/postpartum hemorrhage and evaluate amnioinfusion as a protective factor.

Table 1

Distribution of demographic characteristics and potential risk factors (N=1798)

Characteristic or Factor	Prevalence– n (%)
Maternal Age (years)	24.1±5.4
Oxytocin Dose	
10U	659 (37%)
40U	481 (27%)
80U	658 (37%)
Nulliparity	673 (37%)
Hispanic	327 (18%)
White & Other	410 (23%)
Black	1061 (59%)
Obese (BMI ≥30)	1036 (58%)
Overweight (BMI 25–30)	523 (29%)
Normal, Underweight	239 (13%)
Augmentation	955 (53%)
Induction	572 (32%)
Spontaneous	271 (15%)
Preeclampsia/Eclampsia	218 (12%)
MgSO ₄ Use	188 (10%)
Twins	13 (<1%)
Chorioamnionitis	122 (7%)
Hydramnios	43 (2%)
Amnioinfusion	299 (17%)
Epidural anesthesia	1504 (84%)
Breastfeeding	1000 (57%)
Spontaneous ROM	584 (33%)
Prior Cesarean	86 (5%)
Operative Deliveries	147 (8%)
Anemia	44 (2%)
Protracted 2 nd Stage	108 (6%)
Prolonged 3 rd Stage	35 (2%)

Characteristic or Factor	Prevalence– n (%)
GA at delivery ^a weeks	38.8±2.1
Total birthweight	
<2500g	190 (11%)
2500g –3999g	1499 (83%)
>=4000g	109 (6%)
GA at delivery	
<37 weeks	223 (12%)
37–41 weeks	1395 (78%)
41 weeks	180 (10%)

^a
mean ± standard deviation

Table 2

Incidence of outcome (treated uterine atony) for each factor and unadjusted OR (95% CI)

Factor	Incidence of uterine atony - n (%)	No uterine atony - n (%)	OR (95% CI)
Oxytocin Dose			
10U (n=659)	45 (7%)	614 (93%)	-- referent --
40U (n=481)	31 (6%)	450 (94%)	0.9 (0.6, 1.5)
80U (n=658)	42 (6%)	616 (94%)	0.9 (0.6, 1.4)
Obese (BMI 30) (n=1036)	75 (7%)	961 (93%)	2.6 (1.2, 5.7)
Overweight (BMI 25–30) (n=523)	36 (7%)	487 (93%)	2.5 (1.1, 5.6)
Normal, Underweight (n=239)	7 (3%)	232 (97%)	-- referent --
Hispanic (n=327)	33 (10%)	294 (89%)	2.1 (1.3, 3.3)
White & Other (n=410)	31 (8%)	379 (92%)	1.5 (1.0, 2.4)
Black (n=1061)	54 (5%)	1007 (95%)	-- referent--
Augmentation (n=955)	52 (5%)	903 (95%)	1.2 (0.7, 2.4)
Induction (n=572)	54 (9%)	518 (91%)	2.3 (1.2, 4.3)
Spontaneous (n=271)	12 (4%)	259 (96%)	-- referent--
Birthweight			
<2500g (n=190)	10 (5%)	180 (95%)	0.8 (0.4–1.5)
2500g –3999g (n=1499)	100 (7%)	1399 (93%)	-- referent--
>=4000g (n=109)	8 (7%)	101 (93%)	1.1 (0.5, 2.3)
Nulliparity (n=673)	54 (8%)	619 (92%)	1.4 (1.0, 2.1)
Parity (n=1125)	64 (6%)	1061 (94%)	
Preeclampsia (n=218)	31 (14%)	187 (86%)	2.8 (1.8, 4.4)
No preeclampsia (n=1580)	87 (6%)	1493 (94%)	
MgSO4 Use (n=188)	27 (14%)	161 (86%)	2.8 (1.8, 4.4)
No MgSO4 Use (n=1610)	91 (6%)	1519 (94%)	
Twins (n=13)	2 (15%)	11 (85%)	2.6 (0.6, 12.0)
Singletons (n=1785)	116 (7%)	1669 (93%)	
Chorioamnionitis (n=122)	17 (14%)	105 (86%)	2.5 (1.5, 4.4)
No chorioamnionitis (n=1676)	101 (6%)	1575 (94%)	
Hydramnios (n=43)	5 (12%)	38 (88%)	1.9 (0.7, 5.0)
No hydrmanios (n=1755)	113 (6%)	1642 (94%)	
Amnioinfusion (n=299)	13 (4%)	286 (96%)	0.6 (0.3, 1.1)
No amnioinfusion (n=1499)	105 (7%)	1394 (93%)	

	Incidence of uterine atony - n (%)	No uterine atony – n (%)	OR (95% CI)
Epidural anesthesia (n=1504)	97 (6%)	1407 (94%)	0.9 (0.5, 1.5)
No epidural (n=294)	21 (7%)	273 (93%)	
Breastfeeding (n=1000)	76 (8%)	924 (92%)	1.5 (1.0, 2.2)
No breastfeeding (n=751)	39 (5%)	712 (95%)	
Spontaneous ROM (n=584)	36 (6%)	548 (94%)	0.9 (0.6, 1.4)
Artificial ROM (n=1212)	82 (7%)	1130 (93%)	
Prior Cesarean (n=86)	7 (8%)	79 (92%)	1.3 (0.6, 2.8)
No prior cesarean (n=1712)	111 (6%)	1601 (94%)	
Operative Deliveries (n=147)	12 (8%)	135 (92%)	1.3 (0.7, 2.4)
Nonoperative delivery (n=1651)	106 (6%)	1545 (94%)	
Anemia (Hemoglobin<9) (n=44)	5 (11%)	39 (89%)	1.9 (0.7, 4.8)
No anemia (n=1754)	113 (6%)	1641 (94%)	
Protracted 2 nd Stage (n=108)	14 (13%)	94 (87%)	2.3 (1.3, 4.1)
No protracted 2 nd stage (n=1690)	104 (6%)	1586 (94%)	
Prolonged 3 rd Stage (n=35)	4 (11%)	31 (89%)	1.9 (0.6, 5.4)
No prlonged 3 rd stage (n=1763)	114 (6%)	1649 (94%)	
Maternal Age (years)	24.7 ± 5.7	24.7 ± 5.3	1.0 (1.0, 1.1)
GA at delivery (weeks)	38.9 ± 2.1	38.9 ± 2.1	1.0 (0.9, 1.1)

Table percentages represent the percent with uterine atony (2nd column) and without uterine atony (3rd column) out of all women with the designated characteristic.

Table 3Results of Multivariable Adjusted Analyses: Complementary Models^a

	Strategy A (Traditional Backward)	Strategy B (Modified backward)
Factor	OR (95% CI)	OR (95% CI)
Obese (BMI ≥ 30)	-	2.25 (1.41, 3.62)
Overweight (BMI 25–30)	-	1.48 (0.92, 2.38)
Normal, Underweight	-	Referent
Hispanic	2.10 (1.30, 3.37)	2.26 (1.41, 3.62)
White & Other	1.59 (1.00, 2.53)	1.48 (0.92, 2.38)
Black	Referent	Referent
Augmentation	-	1.08 (0.56, 2.08)
Induction	-	1.60 (0.80, 3.18)
Spontaneous	-	Referent
Preeclampsia	3.15 (2.00, 4.95)	2.61 (1.60, 4.25)
Twins	-	2.64 (0.54, 12.9)
Chorioamnionitis	2.83 (1.61, 4.97)	2.42 (1.35, 4.34)
Hydramnios	-	1.75 (0.65, 4.69)
Amnioinfusion	-	0.53 (0.29, 0.98)
Anemia	-	2.46 (0.92, 6.56)
Protracted 2 nd Stage	-	1.73 (0.92, 3.26)

^a All factors without adjusted results were dropped out of the models based on the specified modeling strategies.